Gene symbol: TSHB

Also known as: TSH-B; TSH-BETA

Organism: Homo sapiens

Summary: The four human glycoprotein hormones chorionic gonadotropin (CG), luteinizing hormone (LH), follicle stimulating hormone (FSH), and thyroid stimulating hormone (TSH) are dimers consisting of alpha and beta subunits that are associated noncovalently. The alpha subunits of these hormones are identical, however, their beta chains are unique and confer biological specificity. Thyroid stimulating hormone functions in the control of thyroid structure and metabolism. The protein encoded by this gene is the beta subunit of thyroid stimulating hormone. Mutations in this gene are associated with congenital central and secondary hypothyroidism and Hashimoto's thyroiditis. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013]

NCBI gene ID: 7252 Ensembl:ENSG00000134200 MIM:188540 AllianceGenome:HGNC:12372


GO Annotation


Category Term ID Term description
Process GO:0007154 Cell communication
Process GO:0007165 Signal transduction
Process GO:0007186 G protein-coupled receptor signaling pathway
Process GO:0007267 Cell-cell signaling
Process GO:0007584 Response to nutrient
Process GO:0009605 Response to external stimulus
Process GO:0009653 Anatomical structure morphogenesis
Process GO:0009719 Response to endogenous stimulus
Process GO:0009725 Response to hormone
Process GO:0009755 Hormone-mediated signaling pathway
Process GO:0009987 Cellular process
Process GO:0009991 Response to extracellular stimulus
Process GO:0010033 Response to organic substance
Process GO:0010035 Response to inorganic substance
Process GO:0010038 Response to metal ion
Process GO:0023052 Signaling
Process GO:0031667 Response to nutrient levels
Process GO:0032502 Developmental process
Process GO:0032870 Cellular response to hormone stimulus
Process GO:0033189 Response to vitamin A
Process GO:0033273 Response to vitamin
Process GO:0033993 Response to lipid
Process GO:0042221 Response to chemical
Process GO:0043627 Response to estrogen
Process GO:0048856 Anatomical structure development
Process GO:0050789 Regulation of biological process
Process GO:0050794 Regulation of cellular process
Process GO:0050896 Response to stimulus
Process GO:0051592 Response to calcium ion
Process GO:0051716 Cellular response to stimulus
Process GO:0065007 Biological regulation
Process GO:0070887 Cellular response to chemical stimulus
Process GO:0071310 Cellular response to organic substance
Process GO:0071495 Cellular response to endogenous stimulus
Component GO:0005576 Extracellular region
Component GO:0005615 Extracellular space
Component GO:0005622 Intracellular anatomical structure
Component GO:0005737 Cytoplasm
Component GO:0032991 Protein-containing complex
Component GO:0061696 Pituitary gonadotropin complex
Component GO:0110165 Cellular anatomical entity
Function GO:0005102 Signaling receptor binding
Function GO:0005179 Hormone activity
Function GO:0005488 Binding
Function GO:0005515 Protein binding
Function GO:0030545 Signaling receptor regulator activity
Function GO:0030546 Signaling receptor activator activity
Function GO:0048018 Receptor ligand activity
Function GO:0098772 Molecular function regulator activity

Pathway annotation


Category Term ID Term description
RCTM HSA-1430728 Metabolism
RCTM HSA-162582 Signal Transduction
RCTM HSA-209776 Metabolism of amine-derived hormones
RCTM HSA-209822 Glycoprotein hormones
RCTM HSA-209952 Peptide hormone biosynthesis
RCTM HSA-209968 Thyroxine biosynthesis
RCTM HSA-2980736 Peptide hormone metabolism
RCTM HSA-372790 Signaling by GPCR
RCTM HSA-373076 Class A/1 (Rhodopsin-like receptors)
RCTM HSA-375281 Hormone ligand-binding receptors
RCTM HSA-388396 GPCR downstream signalling
RCTM HSA-392499 Metabolism of proteins
RCTM HSA-418555 G alpha (s) signalling events
RCTM HSA-500792 GPCR ligand binding
RCTM HSA-71291 Metabolism of amino acids and derivatives
WikiPathways WP2032 Thyroid stimulating hormone (TSH) signaling pathway
WikiPathways WP4746 Thyroid hormones production and peripheral downstream signaling effects
WikiPathways WP5316 Primary ovarian insufficiency

Expression profile of TSHB in omics data



ID GSE120596
Title Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM3405450 1001_baseline cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: baseline library barcode: ATTACTCG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405451 1001_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: post-surgery 1 library barcode: TCCGGAGA-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405452 1002_baseline cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: baseline library barcode: CGCTCATT-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405453 1002_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: post-surgery 1 library barcode: GAGATTCC-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405454 1003_baseline cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: baseline library barcode: ATTCAGAA-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405455 1003_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: post-surgery 1 library barcode: GAATTCGT-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405456 1004_baseline cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: baseline library barcode: CTGAAGCT-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405457 1004_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: post-surgery 1 library barcode: TAATGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder
GSM3405458 1005_baseline cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: baseline library barcode: CGGCTATG-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405459 1005_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-TATAGCCT drug treatment: Placebo response group: Placebo
GSM3405460 1006_baseline cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: baseline library barcode: TCTCGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405461 1006_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: post-surgery 1 library barcode: AGCGATAG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405462 1007_baseline cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: baseline library barcode: ATTACTCG-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405463 1007_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: post-surgery 1 library barcode: TCCGGAGA-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405464 1008_baseline cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: baseline library barcode: CGCTCATT-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405465 1008_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405466 1008_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405467 1011_baseline cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: baseline library barcode: GAATTCGT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405468 1011_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405469 1011_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405470 1012_baseline cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: baseline library barcode: CGGCTATG-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405471 1012_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405472 1012_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder
GSM3405473 1014_baseline cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: baseline library barcode: AGCGATAG-ATAGAGGC drug treatment: Placebo response group: Placebo 0.0
GSM3405474 1014_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405475 1014_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405476 1015_baseline cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: baseline library barcode: CGCTCATT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405477 1015_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405478 1015_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405479 1016_baseline cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: baseline library barcode: GAATTCGT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405480 1016_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405481 1016_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405482 1017_baseline cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: baseline library barcode: CGGCTATG-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405483 1017_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405484 1017_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 2 library barcode: TCTCGCGC-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405485 1018_baseline cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: baseline library barcode: AGCGATAG-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405486 1018_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405487 1018_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405488 1019_baseline cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: baseline library barcode: CGCTCATT-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405489 1019_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405490 1019_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405491 1020_baseline cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: baseline library barcode: GAATTCGT-GGCTCTGA drug treatment: Placebo response group: Placebo
GSM3405492 1020_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-GGCTCTGA drug treatment: Placebo response group: Placebo 0.0
GSM3405493 1020_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-GGCTCTGA drug treatment: Placebo response group: Placebo 0.0
GSM3405494 1021_baseline cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: baseline library barcode: CGGCTATG-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405495 1021_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405496 1021_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405497 1022_baseline cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: baseline library barcode: AGCGATAG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405498 1022_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405499 1022_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405500 1023_baseline cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: baseline library barcode: CGCTCATT-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405501 1023_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405502 1023_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405503 1024_baseline cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: baseline library barcode: GAATTCGT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405504 1024_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405505 1024_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405506 1026_baseline cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: baseline library barcode: CGGCTATG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405507 1026_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405508 1026_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405509 1027_baseline cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: baseline library barcode: AGCGATAG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405510 1027_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405511 1027_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405512 1028_baseline cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: baseline library barcode: CGCTCATT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405513 1028_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405514 1028_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405515 1029_baseline cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: baseline library barcode: GAATTCGT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405516 1029_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405517 1029_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405518 1030_baseline cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: baseline library barcode: CGGCTATG-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405519 1030_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405520 1030_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405521 1032_baseline cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: baseline library barcode: AGCGATAG-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405522 1032_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-CAGGACGT drug treatment: Placebo response group: Placebo 0.0
GSM3405523 1032_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-CAGGACGT drug treatment: Placebo response group: Placebo 0.0
GSM3405524 1033_baseline cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: baseline library barcode: CGCTCATT-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405525 1033_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405526 1033_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0

ID GSE12860
Title Antirheumatic Drug Response in Human Chondrocytes: Potential Molecular Targets to Stimulate Cartilage Regeneration
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM322609 RASF stimulated chondrocytes rep 1 GSM253283 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 5.025653545
GSM322610 RASF stimulated chondrocytes rep 2 GSM253284 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 5.028638981
GSM322611 NDSF stimulated chondrocytes rep 1 GSM253285 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 5.010342545
GSM322612 NDSF stimulated chondrocytes rep 2 GSM253286 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 4.96483832
GSM322613 Chondrocytes stimulated with diclofenac treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 5.227297114
GSM322614 Chondrocytes stimulated with diclofenac treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 5.231314629
GSM322615 Chondrocytes stimulated with prioxicam treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 5.205267538
GSM322616 Chondrocytes stimulated with prioxicam treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 4.985145298
GSM322617 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 5.115747761
GSM322618 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 5.084761513
GSM322619 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 5.063973161
GSM322620 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 5.157432717
GSM322621 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 5.012642856
GSM322622 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 5.024872453
GSM322623 Chondrocytes stimulated with methotrexate treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 5.390089512
GSM322624 Chondrocytes stimulated with methotrexate treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 5.165070754
GSM322625 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 5.222100058
GSM322626 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 5.196215908
GSM322627 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 5.07362114
GSM322628 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 5.074090621

ID GSE150408
Title Identification of key genes potentially related to intervertebral disc degeneration by microarray analysis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM4548691 volunteer-9 tissue: whole blood diagnosis: healthy control treatment: n/a 5.039851883
GSM4548692 volunteer-10 tissue: whole blood diagnosis: healthy control treatment: n/a 2.436470733
GSM4548693 volunteer-11 tissue: whole blood diagnosis: healthy control treatment: n/a 2.422014025
GSM4548694 volunteer-12 tissue: whole blood diagnosis: healthy control treatment: n/a 3.871053154
GSM4548695 volunteer-13 tissue: whole blood diagnosis: healthy control treatment: n/a 5.193606394
GSM4548696 volunteer-14 tissue: whole blood diagnosis: healthy control treatment: n/a 3.996631131
GSM4548697 volunteer-15 tissue: whole blood diagnosis: healthy control treatment: n/a 3.040278629
GSM4548698 volunteer-16 tissue: whole blood diagnosis: healthy control treatment: n/a 3.702470334
GSM4548699 volunteer-17 tissue: whole blood diagnosis: healthy control treatment: n/a 2.718714329
GSM4548700 volunteer-18 tissue: whole blood diagnosis: healthy control treatment: n/a 3.937211923
GSM4548701 volunteer-19 tissue: whole blood diagnosis: healthy control treatment: n/a 4.098665029
GSM4548702 volunteer-20 tissue: whole blood diagnosis: healthy control treatment: n/a 3.306129986
GSM4548703 volunteer-21 tissue: whole blood diagnosis: healthy control treatment: n/a 5.892939699
GSM4548704 volunteer-22 tissue: whole blood diagnosis: healthy control treatment: n/a 3.427695061
GSM4548705 volunteer-23 tissue: whole blood diagnosis: healthy control treatment: n/a 2.60994113
GSM4548706 volunteer-24 tissue: whole blood diagnosis: healthy control treatment: n/a 2.500805897
GSM4548707 volunteer-25 tissue: whole blood diagnosis: healthy control treatment: n/a 3.215161163
GSM4548708 patient-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.990936483
GSM4548709 patient-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.910191414
GSM4548710 patient-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.313341901
GSM4548711 patient-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.94977586
GSM4548712 patient-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.860128243
GSM4548713 patient-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.964855728
GSM4548714 patient-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.009588912
GSM4548715 patient-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.853024872
GSM4548716 patient-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.678030105
GSM4548717 patient-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.828593212
GSM4548718 patient-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.668321303
GSM4548719 patient-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.929687372
GSM4548720 patient-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.444775058
GSM4548721 patient-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.96547708
GSM4548722 patient-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.388614462
GSM4548723 patient-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.979849343
GSM4548724 patient-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.705110553
GSM4548725 treatment-1 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.304175984
GSM4548726 treatment-2 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.333535754
GSM4548727 treatment-3 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.201088543
GSM4548728 treatment-4 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.41715656
GSM4548729 treatment-5 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.828022238
GSM4548730 treatment-6 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.077086537
GSM4548731 treatment-7 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.467937622
GSM4548732 treatment-8 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.761296455
GSM4548733 treatment-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.215953586
GSM4548734 treatment-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.777555558
GSM4548735 treatment-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.70638475
GSM4548736 treatment-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.490759604
GSM4548737 treatment-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.904636264
GSM4548738 treatment-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.173375279
GSM4548739 treatment-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.17313578
GSM4548740 treatment-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.972621808
GSM4548741 treatment-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.787124336
GSM4548742 treatment-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.368007512
GSM4548743 treatment-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.457573727
GSM4548744 treatment-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.32230324
GSM4548745 treatment-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.297279229
GSM4548746 treatment-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.328432987
GSM4548747 treatment-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.632990504
GSM4548748 treatment-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.704668825
GSM4548749 treatment-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.280161124

ID GSE179004
Title Expression data from glioblastoma surgical specimens
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5403447 glioblastoma tissue 1 in TIVA group tissue: glioblastoma 1.503102138
GSM5403448 glioblastoma tissue 2 in TIVA group tissue: glioblastoma 1.193530017
GSM5403449 glioblastoma tissue 3 in TIVA group tissue: glioblastoma 1.503102138
GSM5403450 glioblastoma tissue 1 in INHA group tissue: glioblastoma 1.02627154
GSM5403451 glioblastoma tissue 2 in INHA group tissue: glioblastoma 1.448529593
GSM5403452 glioblastoma tissue 3 in INHA group tissue: glioblastoma 1.32354794

ID GSE212044
Title Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM6508421 IPSC-CM cells, DSMO 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 5.0
GSM6508422 IPSC-CM cells, DSMO 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 3.0
GSM6508423 IPSC-CM cells, DSMO 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 3.0
GSM6508424 IPSC-CM cells, Etomidate 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 3.0
GSM6508425 IPSC-CM cells, Etomidate 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 0.0
GSM6508426 IPSC-CM cells, Etomidate 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 4.0
GSM6508427 IPSC-CM cells, Propofol 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 3.0
GSM6508428 IPSC-CM cells, Propofol 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 5.0
GSM6508429 IPSC-CM cells, Propofol 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 2.0

ID GSE255952
Title Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM8083291 patient C1P1, before first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 3.94098
GSM8083292 patient C1P1, after first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 4.18957
GSM8083293 patient C1P1, before second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.94165
GSM8083294 patient C1P1, after second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.45369
GSM8083295 patient C1P2, before first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.31505
GSM8083296 patient C1P2, after first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.61809
GSM8083297 patient C1P2, before first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.76261
GSM8083298 patient C1P2, after first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.65573
GSM8083299 patient C1P3, before first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.0801
GSM8083300 patient C1P3, after first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.45117
GSM8083301 patient C1P3, before first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.0474
GSM8083302 patient C1P3, after first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.66692
GSM8083303 patient C1P3, before second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp 3.64922
GSM8083304 patient C1P3, after second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none 3.9909
GSM8083305 patient C1P4, before first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.58638
GSM8083306 patient C1P4, after first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.32115
GSM8083307 patient C1P4, before first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.22804
GSM8083308 patient C1P4, after first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.752
GSM8083309 patient C1P5, before first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.84766
GSM8083310 patient C1P5, after first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 4.5988
GSM8083311 patient C1P5, before second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.76942
GSM8083312 patient C1P5, after second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.80935
GSM8083313 patient C2P1, before first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.31519
GSM8083314 patient C2P1, after first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.37562
GSM8083315 patient C2P1, before first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.53901
GSM8083316 patient C2P1, after first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.84185
GSM8083317 patient C2P2, before first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.45846
GSM8083318 patient C2P2, after first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.62291
GSM8083319 patient C2P3, before first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.98307
GSM8083320 patient C2P3, after first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.33103
GSM8083321 patient C2P3, before first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.9745
GSM8083322 patient C2P3, after first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.71816
GSM8083323 patient C2P4, before first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.02937
GSM8083324 patient C2P4, after first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.25426
GSM8083325 patient C2P5, before first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 2.86448
GSM8083326 patient C2P5, after first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.16838
GSM8083327 patient C2P6, before first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.106
GSM8083328 patient C2P6, after first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.91833
GSM8083329 patient C2P7, before first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.35288
GSM8083330 patient C2P7, after first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.2959
GSM8083331 patient C2P8, before first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.90605
GSM8083332 patient C2P8, after first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.88052
GSM8083333 patient C3P1, before second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.90922
GSM8083334 patient C3P1, after second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.90713
GSM8083335 patient C4P1, before first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 4.04662
GSM8083336 patient C4P1, after first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 2.98331
GSM8083337 patient C4P2, before first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.09456
GSM8083338 patient C4P2, after first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 2.82728

ID GSE4386
Title Transcriptomics in cardiac surgery
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM99229 H01_S_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.73512798
GSM99235 H01_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.753022625
GSM99239 H02_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.719050077
GSM99241 H02_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.779970946
GSM99244 H03_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.75979197
GSM99246 H03_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.739717703
GSM99247 H04_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.739842616
GSM99249 H04_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.718479755
GSM99252 H05_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.711594056
GSM99253 H05_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.676493567
GSM99255 H06_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.782046716
GSM99257 H06_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.757141805
GSM99258 H07_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.678233843
GSM99259 H07_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.73782496
GSM99261 H08_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.644880067
GSM99265 H08_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.725949014
GSM99268 H09_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.670841355
GSM99271 H09_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.69493138
GSM99274 H10_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 5.326209628
GSM99277 H10_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 5.160405601
GSM99280 H11_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.597196585
GSM99282 H11_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.672630915
GSM99285 H12_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.761324395
GSM99287 H12_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.812914995
GSM99289 H13_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.701568208
GSM99290 H13_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.862027323
GSM99291 H14_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.7564987
GSM99292 H14_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.762928746
GSM99293 H15_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.760356058
GSM99294 H15_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.961624541
GSM99295 H16_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.81324579
GSM99296 H16_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.83719495
GSM99298 H17_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.684840907
GSM99299 H17_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.743580157
GSM99301 H18_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.983951592
GSM99302 H18_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.795387525
GSM99303 H19_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.687362907
GSM99304 H19_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.75312109
GSM99305 H20_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.683553837
GSM99306 H20_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.67246405

ID GSE56256
Title Influence of hexafluoro-2-propanol (HFIP) on lipopolysaccharides-induced inflammation in human microvascular endothelial cells of the lung
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1357752 7_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 47.493132
GSM1357753 8_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 159.32694
GSM1357754 9_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 70.826466
GSM1357755 4_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 28.174847
GSM1357756 5_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 179.391008
GSM1357757 6_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 42.192913
GSM1357758 11_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 20.056283
GSM1357759 12_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 32.999247000000004
GSM1357760 1_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 37.724484000000004
GSM1357761 2_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 49.122716
GSM1357762 3_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 43.436358

ID GSE59526
Title Affymetrix Chip data of the transcriptome of human clinical study for acupuncture mechanisms on rheumatoid arthritis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1438864 Peripheral blood mononuclear cells from AP group, Patient 2 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: before therapy patient id: 2 37.26135545
GSM1438865 Peripheral blood mononuclear cells from AP group, Patient 3 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: before therapy patient id: 3 6.437841821
GSM1438866 Peripheral blood mononuclear cells from AP group, Patient 6 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: before therapy patient id: 6 43.74666516
GSM1438867 Peripheral blood mononuclear cells from AP group, Patient 8 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: before therapy patient id: 8 39.62293294
GSM1438868 Peripheral blood mononuclear cells from AP group, Patient 9 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: before therapy patient id: 9 39.60676051
GSM1438869 Peripheral blood mononuclear cells from MTX group, Patient 4 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: before therapy patient id: 4 42.36913313
GSM1438870 Peripheral blood mononuclear cells from MTX group, Patient 5 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: before therapy patient id: 5 30.89283298
GSM1438871 Peripheral blood mononuclear cells from MTX group, Patient 7 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: before therapy patient id: 7 7.371730679
GSM1438872 Peripheral blood mononuclear cells from Patient 1 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 1 32.71209905
GSM1438873 Peripheral blood mononuclear cells from Patient 3 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 3 2.582748197
GSM1438874 Peripheral blood mononuclear cells from Patient 1 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 1 23.75764188
GSM1438875 Peripheral blood mononuclear cells from Patient 2 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 2 33.7127608
GSM1438876 Peripheral blood mononuclear cells from Patient 6 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 6 86.01160802
GSM1438877 Peripheral blood mononuclear cells from Patient 8 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 42.6657983
GSM1438878 Peripheral blood mononuclear cells from Patient 9 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 9 4.17771917
GSM1438879 Peripheral blood mononuclear cells from Patient 4 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: after 3 months therapy patient id: 4 39.22852103
GSM1438880 Peripheral blood mononuclear cells from Patient 5 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: after 3 months therapy patient id: 5 38.14552941
GSM1438881 Peripheral blood mononuclear cells from Patient 7 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: after 3 months therapy patient id: 7 42.63871518